TITLE

Court ruling could scupper patent deal

AUTHOR(S)
O'Driscoll, Cath
PUB. DATE
May 2006
SOURCE
ICIS Chemical Business;5/15/2006, Vol. 1 Issue 19, p33
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on a ruling by the European Court of Justice that could make it harder for pharmaceutical companies to obtain patent extensions for certain products in future. The Massachusetts Institute of Technology's application for a so-called supplementary protection certificate (SPC) for its brain cancer drug was rejected because of a technicality concerning the drug composition. The court's ruling effectively supports a decision by the German Patents and Brands Office in 2001, which argued that such combinations qualify for a SPC only if both drug components are active.
ACCESSION #
21046809

 

Related Articles

  • Pharmaceutical Industry to Fight All Effects By Generics Makers to Weaken Patent Protection. Hess, Glenn // Chemical Market Reporter;3/4/2002, Vol. 261 Issue 9, p1 

    Reports the status of pharmaceutical industries due to the existing generic industry in Washington D.C. Proposal for patent extensions; Effect of patent protection on the pharmaceutical industries; Importance of drugs.

  • European Governments Get Carte Blanche to Cut Prices. Houlton, Sarah // Pharmaceutical Executive;Jun2009, Vol. 29 Issue 6, p12 

    The article reports on the decision of the European Court of Justice to a case brought by several pharmaceutical companies against Agenzia Italiana del Farmaco. The pharmacists objected to the decision of Italian medicines agency to reduce the prices of medicines in 2005 and 2006. The court...

  • LEGAL ROUNDUP. Latner, Ann W. // Pharmacy Today;Jul2005, Vol. 11 Issue 7, p13 

    This article presents an update on recent judgments on cases related to the field of pharmacy. It is reported that a U.S. District Court judge has granted Abbott Laboratories Inc.'s request for a preliminary injunction barring Teva Pharmaceutical Industries Ltd. from selling a generic version of...

  • High court to rule on overtime pay. GREENWALD, JUDY // Business Insurance;12/5/2011, Vol. 45 Issue 47, p4 

    The article focuses on the decision of the U.S. Supreme Court to review a case concerning overtime pay of pharmaceutical sales representatives. It makes reference to February decision by the 9th U.S. Circuit Court of Appeals that exempting these sales representatives from GlaxoSmithKline PLC...

  • 'Bioequivalent' Doesn't Protect Generics Makers from Lawsuits.  // Chain Drug Review;7/19/2010, Vol. 32 Issue 12, p63 

    The article presents a 29-page decision of U.S. District Judge Berle Schiller refusing to disregard a suit alleging Impax Laboratories and Teva Pharmaceuticals Ltd. are aware of the problem of anti-depressant drug Wellbutrin but failed to warn the public.

  • Pharmacies charge drugmakers colluding to bar reimportation. Gonzalez, Gloria // Business Insurance;9/6/2004, Vol. 38 Issue 36, p3 

    A lawsuit accusing pharmaceutical companies of charging artificially high prices for U.S. prescription drugs and preventing reimportation of less expensive medicine from Canada is likely to fail unless proof of collusion among the companies is presented, lawyers say. The complaint, which was...

  • US ATTORNEY'S OFFICE Western District of Washington.  // Biomedical Market Newsletter;3/7/2011, p236 

    The article reports on health care professional Drea Lynne Gibson, who has been sentenced to a year and a day in prison, and 3 years of supervised release, after Gibson pleaded guilty for product tampering with doses of Demerol, a narcotic pain medication, in violation of federal law. While...

  • SUPREME COURT TORT RULING DEALS SETBACK TO INDUSTRY. Sissell, Kara // Chemical Week;3/9/2009, Vol. 171 Issue 7, p8 

    The article reports on the decision of the U.S. Supreme Court on the case Wyeth v. Levine. The court ruled that Food and Drug Administration (FDA) approval does not shield drug companies from personal injury suits, a decision that will have major implications for personal injury lawsuits in a...

  • Market Share of Marketed Drugs to Face Erosion by Generic Alternatives.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p495 

    The article reports on the decline of the market share of the world's highest selling marketed drugs for major indications. It is attributed to patent expiry of drugs and generic alternatives which affect the revenue streams of pharmaceutical companies. It is considered that patent extensions...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics